BridgeBio Oncology Therapeutics, Inc. 8-K

What Happened
BridgeBio Oncology Therapeutics, Inc. filed an 8-K on March 26, 2026 announcing that its board increased to nine directors and appointed Peter Lebowitz, M.D., Ph.D., effective March 24, 2026. Dr. Lebowitz will serve as a Class I director with a term expiring at the company’s 2026 annual meeting and has been named to the Nominating & Corporate Governance Committee and the Compensation Committee. The Board has determined he is “independent” under Nasdaq rules.

Key Details

• Board size increased to nine directors; appointment effective March 24, 2026.
• Dr. Lebowitz’s term: Class I director, expires at the 2026 annual meeting of stockholders.
• One-time stock option grant: nonqualified option to purchase 63,350 shares at $8.72/share (Nasdaq closing price on March 24, 2026).
• No related-party arrangements or transactions requiring disclosure; Dr. Lebowitz entered the company’s standard indemnification agreement.
• Director compensation and committee pay will follow the company’s published non-employee director compensation policy.

Why It Matters
This is a governance update that adds an independent director and assigns him to two key oversight committees, which can affect board oversight and corporate governance. The one-time option grant creates potential future dilution if exercised (63,350 shares at an $8.72 exercise price, equal to the market close on the appointment date). The filing does not report any related-party transactions or special arrangements beyond standard indemnification and the company’s normal director pay policy.